****

**Annidis Corporation Announces Financing Arrangements and an International Distribution Agreement**

**OTTAWA, ON, June 17, 2013 –** **Annidis Corporation** (TSX Venture: RHA), creator of the Annidis RHA™, today announced that it has entered into a financing and distribution agreement with Yimai Technology International Company Limited (YIMAI), a Hong Kong company. YIMAI, through an affiliated company, markets and distributes ophthalmology products throughout China.

The terms of the financing transaction are as follows and subject to regulatory approval:

* YIMAI will subscribe for $1 million of the aggregate $3 million, 10% promissory note offering the company announced earlier this year. This will result in the $3 million being fully subscribed. It is anticipated that this non-brokered transaction will close on or before June 20, 2013 contemporaneously with the signing of a distribution agreement.
* YMAI will acquire 20,833,333 common shares from treasury at $0.24 per share in the Company for a total of $5 million resulting in YIMAI having a 23.48 % ownership interest in the company.
* YIMAI will also be issued 6,963,319 common shares which will be held in escrow and will allow YIMAI to maintain its 23.48% ownership interest should the current outstanding warrants, stock options or convertible debenture be exercised or converted to common equity. The shares will be released to YIMAI on the basis of one common share for each 3.26 common shares which are issued upon exercise of the current outstanding warrants, stock options or convertible debenture, if any, and unreleased shares on September 30, 2016 will be cancelled.
* Annidis’ new board will have 7 directors and management will include on its slate of directors 3 individuals nominated by YIMAI of the 7 positions on the board for a minimum three year period.
* YIMAI will have a pre-emptive right to provide Annidis with future financing for a three year period.
* The completion of the $5 million common stock financing is subject to completion of due diligence by YIMAI and approval by the TSX and such other regulatory approvals as are necessary. Subject to due diligence, the transaction is expected to close on or before August 31, 2013.
* YIMAI has agreed to establish a pool of its shares in the Company as an incentive for Annidis staff to be awarded on the basis of achieving business plan objectives.

In addition to the financing transactions, Annidis Health Systems, a wholly-owned subsidiary of the Company, will enter into a distribution agreement with YIMAI which will provide YIMAI with exclusive distribution of Annidis products for the People’s Republic of China, including Hong Kong and Macau.    The term of the agreement is 6 years from the date of regulatory approval in China and is on customary arm’s length terms.

“We believe that the partnership with YIMAI will be a profitable and successful relationship. YIMAI brings expertise in the international marketing and sales of ophthalmological products and its financial commitment provides the capital that will allow Annidis to continue to execute on its strategy for growth. China is an important and growing market with an increasing demand for quality health care.” said CEO Gerald Slemko. “We remain well-positioned to fulfill our committed orders in the second half of the year and fully execute on our sales and growth strategy.”

**About Annidis Corporation**

Annidis (TSX-V: RHA) has developed and is marketing a new imaging platform technology based on Multi-Spectral Imaging (MSI). This new technology is opening a new frontier in disease identification and its management. The Annidis MSI technology allows eye-care professionals to view non-invasively the deepest areas of the eye aiding eye care professionals in the early identification and treatment of debilitating eye diseases. The Company’s existing RHA 2020-U Gold, used by eye care professionals as a broad based tool for detecting early-onset of eye related diseases such as Dry AMD, has a potential market of over 20,000 clinics in North America. The RHA Platinum MD will further strengthen the value proposition allowing doctors to visualize choroidal and retinal vasculature non-invasively. The RHA Platinum MD has global market potential of more than 100,000 Ophthalmologists.

*This news release may contain “forward-looking information” within the meaning of applicable Canadian securities legislation. Statements made in this news release, other than those concerning historical financial information, may be forward-looking and therefore subject to various risks and uncertainties. The words “may”, “will”, “could”, “should”, “would”, “suspect”, “outlook”, “believe”, “plan”, “anticipate”, “estimate”, “expect”, “intend”, “forecast”, “objective”, “hope”, and “continue” (or the negative thereof), and words and expressions of similar import are intended to identify forward-looking statements. Certain material factors or assumptions are implied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. Factors that could cause results to vary include those identified in the Company’s Annual Information Form and other such filings with Canadian securities regulatory authorities, such as the applicability of patents and proprietary technology; possible patent ligation; regulatory approval of products in development; changes in government regulation or regulatory approval processes; government and third party reimbursement; dependence on strategic partnerships; intensifying competition; rapid technological change in the industry; anticipated future losses; the ability to access capital; and the ability to attract and retain key personnel. All forward-looking information presented herein should be considered in conjunction with such filings. Except as required by Canadian securities laws, the Corporation does not undertake to update any forward-looking statements; such statements speak only as of the date made.*

*Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*

**For further information contact:**

Gerald Slemko, CEO

Annidis Corporation

(519) 858-1582 ext. 239

Email: geralds@annidis.com

James Binckly, Investor Relations

TMX Equicom

(416) 815-0700 ext. 228

Email: jbinckly@tmxequicom.com